Sage Therapeutics Encounters Setbacks with Dalzanemdor
Sage Therapeutics, Inc. recently unveiled the topline results from its Phase 2 LIGHTWAVE study, aimed at exploring the effects of dalzanemdor (SAGE-718) in participants who have mild cognitive impairment (MCI) or mild dementia, particularly related to Alzheimer’s Disease (AD).
Study Results and Implications
The LIGHTWAVE study's findings revealed no statistically significant differences from baseline scores in participants treated with dalzanemdor compared to those on a placebo, specifically assessed through the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84, which served as the primary outcome measure.
This particular test evaluates the intellectual capabilities of individuals within the age range of 16 to 90. A total of 174 participants were involved in the study.
In light of these disappointing results, Sage Therapeutics has decided against further clinical development of dalzanemdor for Alzheimer’s treatment. Instead, the company looks ahead to reporting topline data from its Phase 2 DIMENSION Study, focusing on cognitive impairment related to Huntington’s Disease later this year.
Safety and Tolerability of Dalzanemdor
Despite the ineffectiveness noted, dalzanemdor was generally well-tolerated among participants, with no new safety signals emerging throughout the study. The majority of treatment-emergent adverse events were classified as mild to moderate in severity.
Further analysis did not uncover any significant differences between the dalzanemdor-treated group and the placebo group in exploratory endpoints, including the Repeatable Battery for Assessment of Neuropsychological Status (RBANS) and the Montreal Cognitive Assessment (MoCA), both of which are cognitive assessments.
Challenges in Other Trials
In September, Sage announced that Biogen Inc terminated its collaboration and license agreement regarding the SAGE-324 program. This decision came against a backdrop of disappointing outcomes from the Phase 2 KINETIC 2 Study involving the investigational SAGE-324, designed for the chronic treatment of essential tremor (ET).
Impact on Stock Performance
As a direct consequence of these developments, Sage Therapeutics' stock reflected a notable downturn. During the latest market check, SAGE stock plummeted by 11.30%, trading at $5.96 during the premarket session.
Looking Ahead for Sage Therapeutics
The recent study results and ongoing challenges underscore the complexity of drug development, particularly for neurodegenerative disorders. Sage Therapeutics is at a crossroads, with the future of dalzanemdor now uncertain within the Alzheimer’s context. However, the company remains focused on exploring other avenues, specifically its ongoing studies on Huntington’s Disease.
Company Contact Information
For further inquiries, Sage Therapeutics can be contacted through their corporate website. They aim to keep stakeholders and the public updated on any new findings or modifications to their clinical trial strategies.
Frequently Asked Questions
What were the key findings from the LIGHTWAVE study?
The LIGHTWAVE study showed no statistically significant differences in cognitive assessment scores between participants treated with dalzanemdor and those on a placebo.
Is dalzanemdor's development continuing for other conditions?
Following the LIGHTWAVE study, Sage Therapeutics does not plan further development of dalzanemdor for Alzheimer's but will report on its Huntington's Disease studies later this year.
How did dalzanemdor perform in terms of safety?
Dalzanemdor was generally well-tolerated, with mild to moderate treatment-emergent adverse events and no new safety concerns reported.
What impact did the study results have on SAGE stock?
The stock of Sage Therapeutics dropped by 11.30% to $5.96 following the negative outcomes from the Alzheimer’s study.
What collaborations are currently ongoing for Sage Therapies?
Currently, Sage Therapeutics is focusing on its independent studies following the termination of its collaboration with Biogen regarding SAGE-324.
